Cargando…
Mechanisms of Neutralizing Anti-drug Antibody Formation and Clinical Relevance on Therapeutic Efficacy of Enzyme Replacement Therapies in Fabry Disease
Fabry disease (FD) is a rare X-linked lysosomal storage disorder caused by mutations in the α-galactosidase A (AGAL/GLA) gene. The lysosomal accumulation of the substrates globotriaosylceramide (Gb(3)) and globotriaosylsphingosine (lyso-Gb(3)) results in progressive renal failure, cardiomyopathy ass...
Autores principales: | Lenders, Malte, Brand, Eva |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602155/ https://www.ncbi.nlm.nih.gov/pubmed/34748189 http://dx.doi.org/10.1007/s40265-021-01621-y |
Ejemplares similares
-
Neutralizing anti-drug antibodies in Fabry disease have no obvious clinical impact?
por: Lenders, Malte, et al.
Publicado: (2018) -
Assessment and impact of dose escalation on anti-drug antibodies in Fabry disease
por: Lenders, Malte, et al.
Publicado: (2022) -
Pre-existing anti-drug antibodies in Fabry disease show less affinity for pegunigalsidase alfa
por: Lenders, Malte, et al.
Publicado: (2022) -
Impact of enzyme replacement therapy and migalastat on left atrial strain and cardiomyopathy in patients with Fabry disease
por: Pogoda, Christian, et al.
Publicado: (2023) -
Characterization of pre-existing anti-PEG and anti-AGAL antibodies towards PRX-102 in patients with Fabry disease
por: Lenders, Malte, et al.
Publicado: (2023)